Endo Pharmaceuticals presents new mid-stage data evaluating safety and effectiveness of Xiaflex
Saturday, October 01, 2016
Endo Pharmaceuticals presents new phase 2 data evaluating the safety and effectiveness of Xiaflex(collagenase clostridium histolyticum) for dupuytren's disease nodules.
Safety profile of those treated with CCH was generally well tolerated.
Study participants treated with 1 injection of Xiaflex showed statistically significant decrease in size, hardness of dupuytren's disease nodules.
One adverse event was reported as severe (injection site pain with CCH 0.60 mg).
No patients were discontinued from study because of an adverse event.
Source : reuters.com
